ArticlePloS one2026
Potent and broad-spectrum anti-Candida activity of 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one, a triterpenoid from Paullinia pinnata.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis is a common infection that affects women of reproductive age, with a high prevalence among pregnant women. When left untreated, it can lead to pregnancy complications including miscarriage. The study evaluated the activity of the ethyl acetate (EtOAc) extract of Paullinia pinnata and its isolated compound 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one against drug-resistant strains and clinical isolates of Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis and Candida tropicalis. Furthermore, the effects of the combinations of 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one with voriconazole, nystatin or caspofungin on the Candida strains and isolates as well as its antibiofilm activity against the drug-resistant strains are reported in this study. The EtOAc leaves extract of P. pinnata demonstrated considerable activity against the drug-resistant Candida strains and clinical isolates with minimum inhibitory concentrations (MICs) of 31.25 to 500 µg/mL when assessed for anti-Candida activity using the microbroth dilution method. The extract was column fractionated to obtain five bulk fractions, and from the most active bulk fraction, BF4 (MIC = 3.91-31.25 µg/mL), 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one was isolated. This study is the first reported biological activity of the compound. 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one exhibited strong activity against the panel of drug-resistant Candida species with MIC ranging from 0.5 to 16 µg/mL (0.85-27.10 µM). This activity was within similar range to that of ketoconazole (MIC = 1-8 µg/mL) and amphotericin B (MIC = 0.5-2 µg/mL). When combined with voriconazole, nystatin or caspofungin using the checkerboard assay, 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one recorded synergism of 33.33% to 83.33% with the antifungals, with majority of the synergistic interactions observed against C. albicans and C. glabrata strains and isolates. 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one also demonstrated anti-biofilm activity. Its IC50 values against the formation of biofilms and preformed biofilms of the Candida species were 15.30-46.40 μg/mL (25.91-78.60 μM) and 25.40-90.84 μg/mL (43.02-153.86 μM), respectively. In conclusion, P. pinnata possesses strong anti-Candida activity and its isolated compound, 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one displayed potent anti-Candida and anti-biofilm action. These findings identify 6α-(3'-methoxy-4'-hydroxybenzoyl)-lup-20(29)-ene-3-one as a promising anti-Candida compound warranting further investigation, including cytotoxicity in mammalian cells, before its therapeutic potential can be fully assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.